Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

Investigational New Drugs

Volumn 15, Issue 2, 1997, Pages 157-163

  Khorsand, Masoud ^a   Lange, Joan ^a   Feun, Lynn ^b   Clendeninn, Neil J ^c   Collier, Mary ^c   Wilding, George ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c AGOURON PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Aged; Bladder neoplasm; Tetrahydrofolate dehydrogenase inhibitor

Indexed keywords

FOLIC ACID ANTAGONIST; PIRITREXIM;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; URINARY BLADDER NEOPLASMS;

EID: 0030927578     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005860806635     Document Type: Article

References (38)

1. Wingo PA, Tong T, Bolden S: Cancer statistics 1995. CA 45:8-30, 1995
2. Loehrer PJ, Einhorn LH, Elson LH, Crawford PJ, Kuebler ED, Tannock P, Raghavan I, Stuart-Harris DA, Sarosdy R, Lowe MF, Blumenstein BA, Trump D: Randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066, 1992
3. Roth BJ, Bajorin DF: Advanced bladder cancer: The need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin. World J Urol 153:894-900, 1995
4. Fischer GA: Defective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178y leukemia cells. Biochem Pharmacol 11:1233-1234, 1962
5. Flintoff WF, Davidson SV, Siminovitch L: Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. Somatic Cell Gen 2:245-262, 1976
6. Galivan J: Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells. Cancer Res 39:735-743, 1979
7. Niethammer D, Jackson RC: Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer 11:845-854, 1975
8. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ: Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 41:4447-4452, 1981
9. Albrecht AM, Biedier JL and Hitchinson DJ: Two different species of dihydrofolate reductase in mammalian cells differentially resistant to anwthoptetin and methasquin. Cancer Res 32:1539-1546, 1972
10. Alt FW, Kellems RE, Bertino JR, Schimke RT: Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357-1370, 1978
11. Hakala MT, Zakrzewski SF, Nichol CA: Relation of folic reductase to amethopterin resistance in cultured mammalian cells. J Biol Chem 236:952-958, 1961
12. Littlefield J: Hybridization of hamster cells with high and low folate reductase activity. Proc Natl Acad Sci USA 62:88-95, 1969
13. Rosowsky A, Mota CE, Queener SF, Waltham M, Ercikan-Abali E, Bertino JR: 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a sitedirected mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J Med Chem 38(5):745-52, 1995
14. Flintoff WF, Essani K: Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 19:4321-4327, 1980
15. Jackson RC, Hart LI, Harrap KR: Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrofolate reductase. Cancer Res 36:1991-1997, 1976
16. Lewis WS, Cody V, Galisky N, Luft JY, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakely RL: Methotrexate resistant variants of human dihydrofolate reductase with substitution of leucine 22. J Biol Chem 270(10):5057-5064, 1995
17. Chen G, Wright JE, Rosowsky A: Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates. Mol Pharmacol 48(4):758-765, 1995
18. Rosenblatt DS, Whitehead VM: Methotrexate polyglutamates in cultured human cells. Adv Exp Med Biol 163:275-285, 1983
19. Duch DS, Edelstein MP, Bowers SW, Nichols CA: Biochemical and chemotherapeutic studies in 2,4-diamino6 (1,5-dimethoxybenzyl)-5-methyl pyfido (2,3d) pyrimidine (BW 301u). A novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 42:3987-3994, 1982
20. Sigel CW, Macklin AW, Woolley JL, Johnson NW, Collier MA, Blum MR, Clendeninn NJ, Everm BIM, Grebe G, Mackars A, Foss R, Duch DS, Bowers SW, Nichol CA: Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophile inhibitor of dihydrofolate reductase. NCI Monogr 5:111-120, 1987
21. Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MHN: Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake. Cancer Res 45:978-982, 1985
22. Feun LG, Gonzales R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ: Phase II trial of piritrexim in metastatic melanoma using a intermittent, low dose administration. J Clin Oncol 9:464-467, 1991
23. Yokes EE, Dimery IW, Jacobs CD, Karp D, Molina A, Collier MA, Eble ML, Clendeninn NJ: A phase I study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. Cancer 67:2253-2257, 1991
24. Schiesel JD, Carabasi M, Magill G, Casper E, Cheng E, Marks L, Feyzi J, Clendeninn NJ, Smalley R: Oral piritrexim-A phase II study in patients with advanced soft tissue sarcoma. Inv New Drugs 10:97-98, 1992
25. de Wit R, Kaye SB, Roberts JT, Stoter G, Scott J, Verweij J: Oral piritrexim, an effective treatment for metastatic urothelial cancer. Brit J Cancer 67:388-390, 1993
26. de Vries EG, Gietema JA, Workman P, Scott JE, Crawshaw A, Dobbs HT, Dennis, Mulder N, Sleijfer D, Willemse PH: A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. Brit J Cancer 68(3):641-644, 1993
27. Bleehen NM, Newman HV, Rampling RP, Ramsay JR, Roberts JT, Bedford P, Nethersell AB: A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma. Brit J Cancer 72(3):766-768, 1995
28. Feun LG, Savaraj N, Bandito P, Waldman S, Collier M, Glendennin N: Oral piritrexim in advanced bladder cancer: An effective drug after progression on MVAC chemotherapy? Am J Clin Oncol 17(15):448-451, 1994
29. Feun LG, Savaraj N, Benedetro P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, Clendeninn NJ: Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies. J Natl Cancer Inst 83:51-55, 1991a
30. Laszlo J, Brenckman WD, Morgan E, Clendeninn NJ, Williams T, Currie V, Young C: Initial clinical studies of piritrexim NCI Monogr 5:121-125, 1987
31. Yagoda A: Chemotherapy of the urothelial tract tumors. Cancer 60:574, 1987
32. Troner M, Birch R, Omura GA, Williams S: Phase III comparison of cisplatin versus cisplatin doxorubicin and cyclophosphamide in the treatment of bladder (U Jrothelia) cancer: a Southeastern Cancer Study Group trial. J Urol 37(4):660-662, 1987
33. Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR Jr, Coombs J: A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study. Cancer 1,52(5):767-772, 1983
34. Hillcoat BL, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R, Olver I, Bishop J, Pearson B, Coorey G: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7(6):706-709, 1989
35. Khandekar JD, Elson PJ, DeWys WD, Slayton RE, Harris DT: Comparative activity and toxicity of cisdiamminedichloroplatinum (DDP) and a combination of doxorubicin cyclophosphamide and DDP in disseminated transitional cell carcinomas of the urinary tract. J Clin Oncol 3(4):539-545, 1985
36. Roth BJ, Dreicer R, Einhorn LH, et al.: Significant activity of Paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol 12:2264-2270, 1994
37. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5(2):182-184, 1994
38. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ: Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12(11):2271-2276, 1994